The mitochondrial unfolded protein response (UPR mt ) 1
The abbreviations used are: UPR mt , mitochondrial unfolded protein response; ATF5, activating transcription factor 5, IR, ischemia-reperfusion; IPC, ischemic preconditioning; ROS, reactive oxygen species; RPP, rate × pressure product; TTC, tetrazolium chloride; MMP, matrix metalloproteinase; LV, left ventricular is a cytoprotective signaling pathway triggered by mitochondrial dysfunction. Activation of the UPR mt upregulates nuclearencoded mitochondrial genes, including those for chaperones, proteases, and antioxidants, as well as glycolysis, to restore proteostasis and cell energetics. Activating transcription factor 5 (ATF5), a protein with both mitochondrial and nuclear targeting sequences, is proposed to mediate mammalian UPR mt signaling. Since proteostasis and bioenergetics are important in the response of organs such as the heart to injury, we hypothesized that pharmacologic UPR mt activation may be cardioprotective against ischemiareperfusion (IR) injury and that such protection would require ATF5. Using a perfused heart IR injury model in wild-type and global Atf5 -/mice, we found that in-vivo administration of the UPR mt inducers oligomycin or doxycycline 6 h prior to ex-vivo IR injury was cardioprotective. Such protection was absent in hearts from Atf5 -/mice, and no protection was observed with acute ex-vivo cardiac administration of doxycycline. Loss of ATF5 also did not alter baseline IR injury (without UPR mt induction). Cardiac gene expression analysis by RNA-Seq revealed mild induction of numerous genes in an ATF5-dependent manner, which may be important for cardioprotection. Analysis of hearts by qPCR showed that oligomycin at 6 h significantly induced genes encoding ATF5 and several known UPR mt -linked proteins. We conclude that ATF5 is required for cardioprotection induced by drugs that activate the UPR mt . _______________________________________ Tissue ischemia and hypoxia are important pathologic phenomena that underlie disease conditions such as myocardial infarction and stroke. Paradoxically, the reperfusion of ischemic/hypoxic tissues exacerbates injury, and ischemia-reperfusion (IR) injury causes significant morbidity and mortality worldwide (1). In the heart, mitochondria are key mediators of IR injury, and are thus a potential target for cardioprotective interventions (2, 3) .
An important concept in many protective paradigms is hormesis, wherein small sub-lethal insults can trigger cell-signaling events that afford protection against subsequent larger injuries (4). "Mitohormesis" refers to such hormetic events at the mitochondrial level. A classic example is ischemic preconditioning (IPC), wherein small ischemic insults trigger mitochondrial generation of reactive oxygen species (ROS) that signal to induce protection against large-scale pathologic ROS generation during subsequent IR injury (3) .
The mitochondrial unfolded protein response (UPR mt ) is a mitohormetic stress response pathway triggered by proteotoxic stress in the organelle (5) . Similar to other compartmentspecific UPRs (e.g., the endoplasmic reticulum UPR), UPR mt signaling upregulates chaperones to promote protein refolding and proteases to digest misfolded proteins (6) . Furthermore, the UPR mt also upregulates glycolysis (7) and down-regulates expression of mitochondrial respiratory chain subunits (8) to balance cell energetics and reduce burden on the mitochondrial translation and folding machinery.
While the UPR mt was first discovered in mammals (5) , significant insight to this pathway has emerged from work in C. elegans, including the discovery of its central transcription factor ATFS-1 (9) . The ATFS-1 protein contains both nuclear and mitochondrial targeting sequences, and under normal conditions ATFS-1 is imported to mitochondria and degraded (7, 9) . Under conditions of mitochondrial proteotoxicity, ATFS-1 import to the organelle declines, resulting in increased translocation to the nucleus and transcription of target genes (7, 8) .
Comparatively little is known about the mammalian UPR mt , particularly in the heart. The transcription factor ATF5 was proposed as a mammalian ortholog of ATFS-1 (9), and indeed ATF5 can rescue UPR mt signaling in C. elegans lacking ATFS-1 (10) . Previously ATF5 was shown to have roles in cancer (11) , cell cycle regulation (12) , apoptosis (13), neural differentiation (14) and stress signaling (15) . Importantly, to date there has been no in-vivo mammalian evidence that ATF5 is required for UPR mt signaling.
Cardiac IR injury causes bioenergetic dysfunction, protein misfolding, and oxidative stress (16) . The targets of UPR mt signaling include glycolysis, chaperones, proteases, and antioxidants (6) . Accordingly, we previously showed that UPR mt induction was protective against anoxiareoxygenation in C. elegans (17) . Herein we hypothesized that induction of an ATF5-dependent UPR mt may be cardioprotective. against IR injury in mammals.
The mitochondrial ATP synthase inhibitor oligomycin and the tetracycline antibiotic doxycycline are known to induce UPR mt in mammalian cells (10, 18) , likely via disruption of mitochondrial protein import and/or synthesis. Herein we tested the ability of these molecules to elicit cardioprotection in WT (Atf5 +/+ ) and Atf5 -/mice (19) , and we performed gene expression analysis to investigate ATF5-dependent signaling.
Results
The complete original data set for the figures in this paper is deposited at https://www.figshare.com (DOI: 10.6084/m9.figshare.7323929).
Baseline cardiac function and response to IR injury in Atf5 -/mouse hearts
WT (Atf5 +/+ ), Atf5 +/-, and Atf5 -/mice (Fig. S1A/B) were used. Consistent with previous reports (19) (20) (21) , major confounders in these studies were high neonatal mortality and reduced adult body weight of Atf5 -/mice (Fig. S1C/D). Thus, both sexes were used and controls were ageand sex-matched but not always littermates.
Langendorff-perfused ex-vivo hearts were subjected to global IR injury, with cardiac function monitored as rate × pressure product (RPP), and post-IR infarct size assayed by tetrazolium chloride (TTC) staining. Atf5 genotype did not impact post-IR functional recovery or infarct size ( Fig. 1A/B ). Analysis with all genotypes aggregated showed no differences between males and females ( Fig. 1C /D), and further stratification by both sex and genotype did not reveal any sexspecific genotype-dependent effects ( Fig. 1 E/F). Analysis of baseline cardiac function stratified by both sex and genotype showed modest sex effects but no genotype effects ( Fig. S2 ).
ATF5-dependent cardioprotection by oligomycin
Oligomycin induces the UPR mt in mammalian cells (10), so we tested whether oligomycin administration prior to IR injury could elicit cardioprotection. Low-dose oligomycin was administered in-vivo (500 µg/kg) 6 h prior to exvivo IR injury. Hearts from WT oligomycin-mice exhibited significant improvement in post-IR functional recovery (oligomycin 52±4% vs. vehicle 24±4%, p=0.0018) and reduction in infarct size (oligomycin 39±3% vs. vehicle 64±9%, p=0.042) ( Fig. 2A/B ). This protective effect of oligomycin was absent in hearts from Atf5 -/mice (functional recovery: oligomycin 30±4% vs. vehicle 19±5%, p=0.18; infarct: oligomycin 58±6% vs. vehicle 57±8%, p=0.98) ( Fig. 2C /D). Baseline cardiac function prior to IR was similar across groups ( Fig. S3 ).
ATF5-dependent cardioprotection by doxycycline.
Doxycycline is known to elicit cardioprotection against IR injury, via a mechanism proposed to involve matrix metalloproteinases (MMPs) (22) (23) (24) (25) . Since doxycycline also disrupts mitochondrial ribosomal function (26) (27) (28) and activates the UPR mt (18, 29), we hypothesized that it may elicit cardioprotection via the ATF5-dependent UPR mt .
Doxycycline was administered in-vivo (70 mg/kg) 6 h prior to ex-vivo IR injury. Hearts from WT doxycycline-treated mice exhibited significant improvement in post-IR functional recovery (doxycycline 60±8% vs. vehicle 23±4%, p=0.0052) and reduction in infarct size (doxycycline 37±3% vs. vehicle 69±4%, p=0.00046) ( Fig. 3A/B ). This protective effect of doxycycline was absent in hearts from Atf5 -/mice (functional recovery: doxycycline 42±7% vs. vehicle 34±7%, p=0.40; infarct: doxycycline 50±2% vs. vehicle 59±4%, p=0.11) ( Fig. 3C /D). Baseline cardiac function prior to IR was similar across groups (Fig. S4 ).
The ability of doxycycline to induce acute cardioprotection was also tested, by delivering the drug to ex-vivo perfused hearts prior to ischemia and during reperfusion. However, in contrast to previous reports (29) , no significant protective effect was observed (functional recovery: doxycycline 40±19% vs. vehicle 34±9%, p=0.78; infarct: doxycycline 66±6% vs. vehicle 49±5%, p=0.11) ( Fig. 3E/F ).
Genetic analysis of UPR mt activation
To explore the cardioprotective signaling mechanism(s) of UPR mt induction, we performed global gene expression analysis using RNA-Seq on cardiac mRNA from WT or Atf5 -/mice treated with vehicle, oligomycin, or doxycycline. Since both drugs are UPR mt inducers, they were grouped for analysis to identify common genes induced by either drug in WT (adjusted p<0.2), with reduced or no induction in Atf5 -/-(adjusted p<0.4). Such analysis yielded 69 genes, indicating an ATF5dependent response in this model. However, previously reported UPR mt -induced genes (30) were poorly represented in this gene set ( Fig.4 , Table S1 ). Furthermore, an unbiased pathway analysis did not yield useful insights to potential gene programs that may underlie the phenomenon of ATF5-dependent cardioprotection.
To probe the UPR mt transcriptional response more directly, the expression of a set of known UPR mt target genes was analyzed using RT-qPCR. Cardiac mRNA was isolated from WT mice 6 h after administration of oligomycin, and the change in expression due to oligomycin (vs. vehicle) was quantified relative to reference genes (Δ Δ Cq). As expected, the UPR mt -associated genes Hspd1 (HSP60), Clpp, and Lonp, as well as Atf5, were significantly induced by oligomycin, providing evidence of a UPR mt -specific response in the heart. However, expression of Hspa5 which encodes the chaperone BiP in the endoplasmic reticulum UPR was not induced, suggesting no global upregulation of chaperones or other UPR pathways.
DISCUSSION
The key findings of this study are that pharmacologic induction of the UPR mt is cardioprotective in IR injury and that ATF5 is necessary for this cardioprotection. Although a role for ATF5 in the UPR mt has been proposed based on work in C. elegans and mammalian cell culture (10) , this is the first in-vivo demonstration that ATF5 is a necessary component of the canonical UPR mt in mammals. It is also the first study to demonstrate a role for the UPR mt in cardioprotection by tetracycline antibiotics (22) (23) (24) (25) .
The mechanism(s) by which oligomycin or doxycycline activate the UPR mt in-vivo are currently unclear. Since oligomycin inhibits mitochondrial ATP synthase, and protein synthesis generally ranks low in the hierarchy of ATP consuming processes in cells (31) , it is possible that UPR mt induction occurs via impairment of mitochondrial protein synthesis (32) or import (33) , both of which are energy-intensive processes. Importantly, the dose of oligomycin used herein elicited no mortality and did not affect baseline cardiac function (Fig. S3 ). Doxycycline disrupts mitochondrial ribosomal function (26) (27) (28) , and has been demonstrated to induce the UPR mt in mammalian cells (10) , presumably via producing an imbalance between nuclear and mitochondrial DNA encoded subunits of the respiratory chain (18).
A single bolus injection of oligomycin or doxycycline 6 h prior to IR elicited significant cardioprotection in WT mice, indicating that mitochondrial proteotoxic stress is a hormetic mechanism of cardioprotection, akin to other cardioprotective paradigms such as delayed preconditioning, wherein a primary stress induces a gene program that protects against subsequent similar stress (34). In the case of UPR mt , this gene program includes chaperones, proteases, antioxidants, and a shift away from mitochondrial oxidative metabolism toward glycolysis (6) (7) (8) , all of which would be predicted to confer benefits during IR injury.
Cardioprotection conferred by pharmacologic UPR mt induction was absent in Atf5 -/mice. Importantly, there was no change in baseline IR injury with ATF5 genotype and no difference in baseline cardiac function between drug treatment groups, thus indicating the loss of cardioprotection in Atf5 -/mice was not due to an increased sensitivity to IR injury or underlying effects of the UPR mt -inducing drugs on cardiac function.
Although RNA-Seq analysis led to the identification of several genes induced by either oligomycin or doxycycline in an ATF5-dependent manner, none of these were known UPR mt targets. In contrast, qPCR identified a modest but significant increase in cardiac mRNA expression for several UPR mt -associated genes in oligomycintreated mice. This discrepancy could be due to the low overall sensitivity of RNA-Seq relative to qPCR.
A potential confounder for the use of doxycycline to induce the UPR mt in the context of cardioprotection is its reported ability to confer cardioprotection when administered post-IR injury via inhibiting MMPs (22) (23) (24) (25) . A human clinical trial was based on such findings (NCT00469261), and the proposed mechanisms for MMP inhibition by doxycycline include divalent metal chelation (35) and redox activity (36). However, our data indicate that doxycycline-induced cardioprotection requires ATF5. To the best of our knowledge there is no connection between ATF5 and MMPs, and no MMP genes emerged from our RNA-Seq analysis. Furthermore, the structurally unrelated UPR mt -inducer oligomycin also yielded ATF5dependent cardioprotection, suggesting the UPR mt /ATF5 axis is a standalone mechanism of doxycycline inducible cardioprotection, independent from MMPs.
Although herein we chose a 6 h delay between drug administration and IR injury, to permit induction of the UPR mt gene program, a recent report claimed acute cardioprotection by tetracycline antibiotics delivered 30 min prior to ischemia (29) . Our inability to reproduce this phenomenon may have been due to an observed low solubility of doxycycline in Krebs-Henseleit perfusion buffer, such that the microfiltration necessary for successful mouse cardiac perfusion (37) may have limited doxycycline bioavailability in our experiments. In addition, a 30 min pretreatment is likely too short for induction of a genetic stress response such as the UPR mt (38) . Thus, acute tetracycline cardioprotection is likely attributable to MMP-inhibition, as previously shown (22) .
The current results are the first to cement a role for ATF5 as the central mediator of the canonical UPR mt in mammals at the whole animal level. While the UPR mt has been extensively characterized in C. elegans, it remains unclear whether the mammalian UPR mt retains all features observed in the model organism. For example, the nematode UPR mt involves several proteins with potential but unproven orthologs in mammals, including DVE-1 (SATB2) and UBL-5 (UBL5) (39) . Another key feature of the UPR mt uncovered in C. elegans is its potential for cell nonautonomous signaling, whereby UPR mt induction in one cell or organ can trigger protection against stress in another (40) . In this regard, we observed mild induction of the UPR mt in hearts of oligomycin-treated animals, but it should be noted that we utilized a global Atf5 -/mouse. As such, we cannot exclude the possibility that pharmacologic ATF5-dependent UPR mt induction in-vivo may have occurred in a tissue other than the heart, with a blood-borne or other signal eliciting remote cardioprotection via ATF5-independent mechanisms. Further studies utilizing tissuespecific Atf5 -/animals may therefore prove insightful.
Experimental procedures Reagents, animals
All reagents were from Sigma (St. Louis, MO) unless otherwise stated. All animal experiments were approved by the Committee on Animal Resources of the University of Rochester (Protocol #UCAR-2014-036) in compliance with the NIH Guide for the Care and Use of Laboratory Animals: 8 th edition (revised 2011). Founder Atf5 -/+ mice were provided by Stavros Lomvardas on a C57BL/6(J/N) background (19) and backcrossed to C57BL/6J (000664) from JAX (Bar Harbor, ME) at least three generations. Mice were housed with a 12-hour light/dark cycle, with ad libitum food and water. Experimental mice were 12-20 week adults of both sexes (n=131). WT (Atf5 +/+ ) controls were age-and sex-matched, as the high neonatal mortality of Atf5 -/mice made using littermates infeasible. PCR genotyping was performed at 21 days by analyzing tail clip DNA with a mix of 3 primers, with expected amplicon sizes of 1006bp for the WT allele and 439bp for the knockout allele: WT:5'-TCTGATTGGATGACTGAGCGG-3' KO:5'-GCAGCCTCTGTTCCACATACACTTC-3' Common: 5'-TCACTTGTGTTCCAAGTCCCC-3'
Perfused heart IR injury model
IR injury was assessed using an ex-vivo Langendorff perfused heart model as previously described (41) . Following intraperitoneal administration of anesthetic (tribromoethanol, 200 mg/kg) and heparin (0.2 mL), each mouse was placed supine on a 37°C warming pad, and the aorta cannulated with a blunt 37 G needle followed by immediate transfer to the perfusion rig. Perfusion was at 4 mL/min with 37°C, 0.22µm filtered, Krebs-Henseleit buffer comprising: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO 4 , 25 mM NaHCO 3 , 1.2 mM K 2 HPO 4 , gassed with 95% O 2 /5% CO 2 . Additionally 5 mM glucose, 100 µM palmitate-BSA, 200 µM pyruvate, and 1.2 mM lactate were present as metabolic substrates. Left ventricular (LV) pressure was measured by a transducer-linked water-filled LV balloon, with digital recording (DATAQ, Akron, OH). LV pressure traces were analyzed using a custom MATLAB program (MathWorks, Natick, MA), to calculate developed pressure (dP), heart rate (HR), rate × pressure product (RPP), and maximal rate of rise (+dP/dt max ). Hearts were equilibrated for 25 min, then subjected to 25 min global no-flow ischemia followed by 60 min reperfusion. Post-IR hearts were transverse sliced (2 mm thick), stained with 1% tetrazolium chloride (TTC), fixed in formalin for 24 h, and slices imaged. Images were digitally segmented (healthy red tissue vs. infarcted white tissue) and pixel counts quantified using a custom MATLAB program.
Drug Treatments
For in-vivo experiments, oligomycin (Sigma O4876, 500 µg/kg) or doxycycline (Sigma D9891, 70 mg/kg) were administered via intraperitoneal injection in a vehicle comprising of sterile normal saline with 0.1% DMSO (injection volume 12.5 µL/g body weight). Controls received vehicle alone. Mice were returned to cages for 6 h prior to experiments. For ex-vivo experiments, doxycycline (20 µM) was dissolved in perfusion buffer containing 0.25% DMSO, followed by 0.2 µm filtration. Doxycycline-containing buffer was perfused throughout pre-ischemic equilibration and reperfusion.
RNASeq and qPCR
Following anesthesia (tribromoethanol, 200 mg/kg) hearts were excised, flushed with icecold saline, homogenized in TRIzol reagent (Invitrogen, Carlsbad, CA), snap-frozen (liquid N 2 ) and stored at -80°C overnight. RNA was processed from TRIzol according to the manufacturer's instructions and further purified using a RNeasy Minikit (Qiagen, Hilden, Germany) coupled with on-column DNase treatment.
For RNA-Seq, library preparation and analysis were performed by the Functional Genomics Core at the University of Rochester (oligomycin experiments) or the Integrated Genomics Operation at Memorial Sloan Kettering Cancer Center (doxycycline experiments). Total RNA concentration was determined spectrophotometrically (NanoDrop 1000, Wilmington, DE) and RNA quality assessed with the Agilent Bioanalyzer (Agilent, Santa Clara, CA). Library construction and next-generation sequencing was performed from 200 ng RNA with the TruSeq Stranded mRNA Sample Preparation Kit and a HiSeq 2500 v4 platform with cBot according to manufacturer's protocols (Illumina, San Diego, CA). Raw reads were demultiplexed using bcl2fastq.pl v1.8.4 conversion software (Illumina). Quality filtering and adapter removal were performed using Trimmomatic version 0.32 (42) , then processed/cleaned reads were mapped to the mouse genome with STAR 2.4.2a (43) .
For qPCR, cDNA was generated using an iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) and used at 100 µg/well as a PCR template for target detection with iTaq Universal SYBR Green Supermix (Bio-Rad) on a CFX Connect Real-Time PCR Detection System (Bio-Rad). Quantification cycle (Cq) of each RT-qPCR targets was normalized to that of the reference genes actin (Actb) or Hprt (Δ Cq). Primers and expected amplicon sizes are in Table S2 . Data are presented in treated vs. untreated (vehicle) conditions as relative Δ Cq (i.e., Δ Δ Cq).
Statistics
Comparisons between 2 groups were performed using two-tailed, unpaired Student's ttests. Comparisons versus zero (Fig. 5) were performed by two-tailed, one-sample Student's ttests. Univariate comparisons between more than 2 groups (Fig. 1A/B ) were performed by one-way ANOVA. Multivariate comparisons between groups ( Fig. 1E/F, S2 , S3, S4) were performed by two-way ANOVA. In all cases, differences were considered significant for p<0.05. Data are reported as means±SEM.
RNA-Seq gene read counts were processed using the open source R/Bioconductor software suite (R version 3.4.4; Bioconductor version 3.7; limma version 3.34.9). One sample from an Atf5 -/mouse which received vehicle was removed prior to analysis because it contained reads that mapped to the Atf5 gene indicating that it may not have been a true knockout. Genes with fewer than 50 reads in all samples were filtered prior to analysis, yielding 14,061 genes used in all subsequent analyses. The voom method (44) was used to estimate the mean-variance relationship of the logged gene counts and calculate a precision weight for each observation. These weights were then used with limma empirical Bayes analysis methodology (45) Table S1 . Full data set has been deposited in the Sequence Read Archive (SRA) under accession number SRP150238. 
